drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Chimeric IgG1 monoclonal antibody targeting TNF-α; binds soluble and membrane TNF-α to block TNFR1/2 signaling, dampening NF-κB/MAPK pathways, reducing pro-inflammatory cytokines and leukocyte trafficking, and potentially inducing apoptosis of activated T cells/macrophages to promote mucosal healing.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody against TNF-α; binds soluble and transmembrane TNF-α to prevent TNFR1/2 signaling, suppressing NF-κB/MAPK–mediated inflammation, lowering pro‑inflammatory cytokines and leukocyte trafficking, and can induce apoptosis of activated immune cells to promote mucosal healing.
drug_name
Infliximab
nct_id_drug_ref
NCT05660746